media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

SEACare 2026

Organiser：Malaysia ABC Exhibition Company Time：April 28 – 30, 2026 Address：8, Jalan Dutamas 2, Kompleks Kerajaan, 50480 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia Exhibition hall：Malaysia International Trade and Exhibition Centre Product range: Medical and Hospital Institution Equipment: institutional equipment, dental products, disposable items, medical staff attire, nursing supplies, etc. Electronic Medical Equipment: anesthesia instruments, audiometers, blood pressure monitors, laser equipment, surgical instruments, scanning devices Medical Laboratories: analytical instruments, microbiology, blood analysis, biochemical equipment, etc. Rehabilitation and Home Care: assistive and physical therapy equipment, rehabilitation devices, orthotic devices, sports facilities, wheelchairs, etc. Pharmaceutical Products: consumer products and herbal preparations, etc. About SEACare 2026 ： The Malaysia Kuala Lumpur Medical Equipment and Rehabilitation Exhibition (SEACare) is one of the most renowned exhibitions in the region and serves as a crucial avenue for Chinese enterprises to explore the Malaysian market. It undoubtedly presents an excellent opportunity for our medical institutions to gain access to ...
- Source: drugdu
- 47
- January 15, 2026
First Dry Powder Inhaler from a Chinese Pharmaceutical Company Approved by FDA for U.S. Marketing

On January 12, 2026 (U.S. time), Runsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Runsheng Pharmaceutical”) announced exciting news: its submitted product Fluticasone Propionate and Salmeterol Inhalation Powder (USAN: Fluticasone Propionate and Salmeterol Inhalation Powder USP, ANDA No.: 214464) has officially obtained marketing approval from the U.S. Food and Drug Administration (FDA). This marks the first-ever FDA approval of a dry powder inhaler (DPI) independently developed by a Chinese pharmaceutical company, representing a pivotal breakthrough for China’s high-end complex drug formulations to penetrate the international mainstream market. Formulated as a fixed-dose combination therapy integrating a bronchodilator and an inhaled corticosteroid, this product is specifically indicated for the maintenance treatment of reversible airway obstructive diseases such as asthma in adults and pediatric patients. Picture source: Boteng Pharmaceuticals 01 Originator Background: The Market Foundation of a Multi-Hundred-Billion-Dollar Product The originator of this product is Advair® Diskus®, developed by the UK-based GlaxoSmithKline (GSK). ...
- Source: drugdu
- 78
- January 14, 2026
Sino Biopharmaceutical Acquires Hangzhou Hygieia Biomedical

On January 13, Hong Kong-listed pharmaceutical leader Sino Biopharmaceutical (1177.HK) issued an announcement, declaring the full acquisition of domestic siRNA innovative drug company Hangzhou Hygieia Biomedical for a total price of RMB 1.2 billion. According to available data, Hygieia Biomedical was established in 2018 and is committed to providing innovative siRNA products with ultra-long action and low dosage advantages. The core R&D team, led by founder and chief scientist Dr. Cui Kunyuan, possesses over 20 years of professional experience in the development of small nucleic acid drugs, securing more than 50 core patents covering multiple delivery systems. Leveraging this profound technical accumulation, Hygieia has established six major intrahepatic and extrahepatic delivery platforms. Currently, four innovative drug candidates have advanced into the clinical stage, with over 20 projects in the preclinical phase, and the company has achieved two external licensing agreements. These pipelines hold significant potential as global First-in-Class (FIC) and ...
- Source: drugdu
- 70
- January 14, 2026
U.S. FDA Accepts Investigational New Drug (IND) Application for LAE118

China Securities Intelligent Finance: Laekna, Inc. (02105.HK) announced on the morning of January 14 that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a novel pan-mutation selective PI3Kα inhibitor. The drug is intended for the treatment of patients with PIK3CA-mutated solid tumors. The company stated it will collaborate closely with regulatory authorities to advance the application and is committed to providing this precision therapy to cancer patients in need of new treatment options. LAE118 is a key candidate that the company is actively progressing into clinical research. https://finance.eastmoney.com/a/202601143618541346.html
- Source: drugdu
- 46
- January 14, 2026
Another boost to domestically developed vaccines! Baihui Biotechnology’s human diploid cell rabies vaccine approved for clinical trials

On January 12, 2026, the National Medical Products Administration (NMPA) officially issued a Clinical Trial Approval Notice (Acceptance No.: CXSL2500917, Registration Category 3.3) to Beijing Baihui Biotechnology Co., Ltd. and Bohui Biopharmaceutical Co., Ltd. for their jointly submitted freeze-dried human rabies vaccine (human diploid cell). This vaccine, incorporating multiple technological innovations, has successfully entered the clinical trial stage, marking a key breakthrough for Baihui Biotechnology in the field of viral vaccine development and providing a new localized solution for rabies prevention and control in my country. pictureRabies has a near 100% mortality rate, making prevention and control an urgent need. Rabies, an acute infectious disease of the central nervous system caused by the rabies virus, is a public health nightmare due to its lethality. Data shows that approximately 59,000 people die from the disease globally each year, with the majority of deaths occurring in developing countries. After onset, patients exhibit ...
- Source: drugdu
- 44
- January 14, 2026
Eli Lilly’s oral weight loss drug has been submitted for marketing approval in China

According to data from PharmNet, Eli Lilly has submitted a marketing application to the NMPA for orforglipron . Previously, at the end of 2025, Eli Lilly had submitted a New Drug Application (NDA) for the same drug to the U.S. FDA for the treatment of obesity or overweight in adults. Orforglipron (formerly known as OWL833) was first discovered by Chugai Pharmaceutical Co., Ltd. In September 2018, Chugai Pharmaceutical signed a global exclusive licensing agreement with Eli Lilly and Company, under which Eli Lilly and Company will obtain the global rights to develop and commercialize OWL833. According to the results of Eli Lilly’s Phase 3 clinical trial ATTAIN-2, orforglipron showed significant efficacy and a safety profile consistent with injectable GLP-1RA drugs. In obese or overweight participants with type 2 diabetes (a population that is more difficult to lose weight), during the 72-week treatment period, the mean weight loss was 10.4 kg ...
- Source: drugdu
- 44
- January 14, 2026
Isaconazole sulfate API approved for market launch, expanding into the antifungal drug field

Shanghai Pharmaceuticals (601607) announced on the evening of January 13 that its subsidiary, Shanghai Pharmaceutical Kangli (Changzhou) Pharmaceutical Co., Ltd., received the ” Chemical Raw Material ” certificate for isaconazole sulfate raw material issued by the National Medical Products Administration.The drug was officially approved for production upon receiving the “Notification of Approval for Drug Marketing Application”. The announcement indicates that isaconazole sulfate is an azole antifungal drug and a prodrug of isaconazole. After entering the body, it is rapidly converted into the active metabolite isaconazole by plasma esterases, which disrupts fungal cell membrane formation by inhibiting ergosterol biosynthesis. This drug was jointly developed by Astellas Pharma and Basellia Pharma, and was approved for marketing in the United States in 2015 for the treatment of invasive aspergillosis and mucormycosis in adults. It has been granted orphan drug status in both the European Union and the United States. Shanghai Pharmaceuticals Kangli submitted ...
- Source: drugdu
- 43
- January 14, 2026
WuXi Biologics Receives UK MHRA GMP Certification, Accelerating Commercial Production of Innovative Ophthalmic Biologics

WuXi Biologics recently announced that its two manufacturing plants in Wuxi—Plant 5 (DP5) and the Formulation Packaging Centre (DPPC)—have received GMP certification from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to provide commercial manufacturing services for an innovative ophthalmic biologic. WuXi Biologics will provide end -to-end manufacturing services for this ophthalmic biologic, covering both the drug substance and the formulation. https://finance.eastmoney.com/a/202601133616465680.html
- Source: drugdu
- 46
- January 14, 2026
【EXPERT Q&A】What is the primary condition for the registration of imported medical devices?

Drugdu.com expert’s response: The primary condition for the registration of imported medical devices is that the product must have been approved for marketing and sales in the country (or region) where the applicant or filer is registered or where the manufacturing address is located. This condition serves as the foundation for ensuring the legality and safety of imported medical devices, and can be understood from the following aspects: Legal Basis Article 13 of the Medical Device Registration Regulations (Order No. 4 of the CFDA) explicitly stipulates that imported medical devices applying for registration or filing must have been approved for marketing and sales in the country (or region) where the applicant or filer is registered or where the manufacturing address is located. The Regulations on the Supervision and Administration of Medical Devices also emphasize the requirement for imported medical devices to have been marketed abroad, ensuring compliance with international or local medical device regulatory ...
- Source: drugdu
- 49
- January 14, 2026
NVIDIA and Eli Lilly jointly invested 1 billion US dollars to establish an AI drug research laboratory

China Securities News (Intern Yang Yanying, Reporter Wang Zhoujie) – On January 12th local time, NVIDIA and the pharmaceutical company Eli Lilly announced that they would jointly invest 1 billion US dollars to establish an AI drug research laboratory in San Francisco to accelerate the drug development process. This 1 billion US dollar investment will be used over five years for the infrastructure, computing power and talent deployment of the laboratory. Engineers from NVIDIA will collaborate with experts in biology, science and medicine from Eli Lilly to advance medical research. The related work of the laboratory will start at the beginning of this year. Eli Lilly’s CEO David Ricks said, “Combining our vast data and scientific knowledge with NVIDIA’s computing capabilities and model construction expertise may completely reshape the way we know drug development.” In the medical and health field, NVIDIA has previously invested in the biotechnology company Recursion and ...
- Source: drugdu
- 54
- January 13, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.